|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006118,
umls-concept:C0008976,
umls-concept:C0023981,
umls-concept:C0034656,
umls-concept:C0070165,
umls-concept:C0087111,
umls-concept:C0113600,
umls-concept:C0680218,
umls-concept:C0750974,
umls-concept:C1257890,
umls-concept:C1274040,
umls-concept:C2603343
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1995-5-18
|
|
pubmed:abstractText |
A two-arm randomized clinical trial was performed to determine the efficacy of PCNU and AZQ in the treatment of de novo or recurrent primary brain tumors. An additional objective was to gather information on the administration and toxicity of these compounds, supplementing that obtained previously in phase I/II studies.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0167-594X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
22
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
55-65
|
|
pubmed:dateRevised |
2010-3-24
|
|
pubmed:meshHeading |
pubmed-meshheading:7714551-Antineoplastic Agents,
pubmed-meshheading:7714551-Aziridines,
pubmed-meshheading:7714551-Benzoquinones,
pubmed-meshheading:7714551-Brain Neoplasms,
pubmed-meshheading:7714551-Child,
pubmed-meshheading:7714551-Humans,
pubmed-meshheading:7714551-Middle Aged,
pubmed-meshheading:7714551-Nitrosourea Compounds,
pubmed-meshheading:7714551-Prospective Studies,
pubmed-meshheading:7714551-Recurrence,
pubmed-meshheading:7714551-Survival Analysis
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
Superiority of PCNU over AZQ in the treatment of primary brain tumors: results of a prospective randomized trial (81-20) by the Brain Tumor Study Group.
|
|
pubmed:affiliation |
Memorial Sloan-Kettering Cancer Center, Department of Neurology, New York, NY 10021-6007, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial
|
